CoChat
Sign Up
Cited by 209Mitochondrial Function and PathologyCoenzyme Q10 studies and effectsNeurological Disorders and Treatments

Mitochondria-Targeted Drugs

Open access
Zinovkin, Roman A., Zamyatnin, Andrey A.·2019·Current Molecular Pharmacology
DOI 10.2174/1874467212666181127151059PMC PMC6875871
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Targeting of drugs to the subcellular compartments represents one of the modern trends in molecular pharmacology. The approach for targeting mitochondria was developed nearly 50 years ago, but only in the last decade has it started to become widely used for delivering drugs. A number of pathologies are associated with mitochondrial dysfunction, including cardiovascular, neurological, inflammatory and metabolic conditions. Objective: This mini-review aims to highlight the role of mitochondria in pathophysiological conditions and diseases, to classify and summarize our knowledge about targeting mitochondria and to review the most important preclinical and clinical data relating to the antioxidant lipophilic cations MitoQ and SkQ1. Methods: This is a review of available information in the PubMed and Clinical Trials databases (US National Library of Medicine) with no limiting period. Results and Conclusion: Mitochondria play an important role in the pathogenesis of many diseases and possibly in aging. Both MitoQ and SkQ1 have shown many beneficial features in animal models and in a few completed clinical trials. More clinical trials and research efforts are needed to understand the signaling pathways influenced by these compounds. The antioxidant lipophilic cations have great potential for the treatment of a wide range of pathologies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1874467212666181127151059

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pharmacophore molecules linked to lipophilic cation moieties, such as triphenylphosphonium (TPP+), can successfully penetrate biological membranes and realize negatively charged intramitochondrial localization.

    “Pharmacophore molecules linked to lipophilic cation moieties, such as triphenylphosphonium (TPP+), can successfully penetrate biological membranes and realize the negatively charged intramitochondrial localization (23).”

    From Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review (2023) · cites this paper as [23]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 110

  1. [1]Davis S.S. Biomedical applications of nanotechnology--implications for drug targeting and gene therapy. Trends Biotechnol. 1997 15 6 217 224 9183864
  2. [2]Keservani R.K. Sharma A.K. Kesharwani R.K. Drug Delivery Approaches and Nanosystems, Volume 2: Drug Targeting Aspects of Nanotechnology. CRC Press 2017
  3. [3]Burns R.J. Smith R.A. Murphy M.P. Synthesis and characterization of thiobutyltriphenylphosphonium bromide, a novel thiol reagent targeted to the mitochondrial matrix. Arch. Biochem. Biophys. 1995 322 1 60 68 7574695
  4. [4]Wallace D.C. Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochondrion 2010 10 1 12 31 19796712 PMC3245717
  5. [5]Nicholls D.G. Bernson V.S. Heaton G.M. The identification of the component in the inner membrane of brown adipose tissue mitochondria responsible for regulating energy dissipation. Experientia Suppl. 1978 32 89 93 348493
  6. [6]Bagur R. Hajnóczky G. Intracellular Ca2+ Sensing: Its Role in Calcium Homeostasis and Signaling. Mol. Cell 2017 66 6 780 788 28622523 PMC5657234
  7. [7]Clapham D.E. Calcium signaling. Cell 2007 131 6 1047 1058 18083096
  8. [8]Lemasters J.J. Molecular Mechanisms of Cell Death. Molecular Pathology. Elsevier 2018 1 24
  9. [9]Kim J-S. He L. Lemasters J.J. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem. Biophys. Res. Commun. 2003 304 3 463 470 12729580
  10. [10]Kalkavan H. Green D.R. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 2018 25 1 46 55 29053143 PMC5729535
  11. [11]Chautan M. Chazal G. Cecconi F. Gruss P. Golstein P. Interdigital cell death can occur through a necrotic and caspase-independent pathway. Curr. Biol. 1999 9 17 967 970 10508592
  12. [12]Angelova P.R. Abramov A.Y. Functional role of mitochondrial reactive oxygen species in physiology. Free Radic. Biol. Med. 2016 100 81 85 27296839
  13. [13]Zorov D.B. Juhaszova M. Sollott S.J. Mitochondrial ROS-induced ROS release: an update and review. Biochim. Biophys. Acta (BBA)-. Bioenergetics 2006 1757 5-6 509 517 16829228
  14. [14]Orrenius S. Gogvadze V. Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annu. Rev. Pharmacol. Toxicol. 2007 47 143 183 17029566
  15. [16]Angelova P.R. Kasymov V. Christie I. Sheikhbahaei S. Turovsky E. Marina N. Korsak A. Zwicker J. Teschemacher A.G. Ackland G.L. Funk G.D. Kasparov S. Abramov A.Y. Gourine A. V Functional Oxygen Sensitivity of Astrocytes. J. Neurosci. 2015 35 29 10460 10473 26203141 PMC4510287
  16. [18]Klebanoff S.J. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 2005 77 5 598 625 15689384
  17. [19]Kellogg E.W. Fridovich I. Superoxide, hydrogen peroxide, and singlet oxygen in lipid peroxidation by a xanthine oxidase system. J. Biol. Chem. 1975 250 22 8812 8817 171266
  18. [20]Pizzinat N. Copin N. Vindis C. Parini A. Cambon C. Reactive oxygen species production by monoamine oxidases in intact cells. Naunyn Schmiedebergs Arch. Pharmacol. 1999 359 5 428 431 10498294
  19. [21]Montezano A.C. Touyz R.M. Reactive oxygen species and endothelial function--role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin. Pharmacol. Toxicol. 2012 110 1 87 94 21883939
  20. [22]Sahoo S. Meijles D.N. Pagano P.J. NADPH oxidases: key modulators in aging and age-related cardiovascular diseases? Clin. Sci. (Lond.) 2016 130 5 317 335 26814203 PMC4818578
  21. [24]Rastogi R. Geng X. Li F. Ding Y. NOX Activation by Subunit Interaction and Underlying Mechanisms in Disease. Front. Cell. Neurosci. 2016 10 301 28119569 PMC5222855
  22. [26]Zinovkin R.A. Romaschenko V.P. Galkin I.I. Zakharova V.V. Pletjushkina O.Y. Chernyak B.V. Popova E.N. Role of mitochondrial reactive oxygen species in age-related inflammatory activation of endothelium. Aging (Albany NY) 2014 6 8 661 674 25239871 PMC4169860
  23. [27]Mukhopadhyay P. Horváth B. Zsengellér Z. Zielonka J. Tanchian G. Holovac E. Kechrid M. Patel V. Stillman I.E. Parikh S.M. Joseph J. Kalyanaraman B. Pacher P. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic. Biol. Med. 2012 52 2 497 506 22120494 PMC3253235
  24. [29]Lightowlers R.N. Taylor R.W. Turnbull D.M. Mutations causing mitochondrial disease: What is new and what challenges remain? Science 2015 349 6255 1494 1499 26404827
  25. [31]Kelley D.E. He J. Menshikova E.V. Ritov V.B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002 51 10 2944 2950 12351431
  26. [32]Ritov V.B. Menshikova E.V. Azuma K. Wood R. Toledo F.G.S. Goodpaster B.H. Ruderman N.B. Kelley D.E. Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. Am. J. Physiol. Endocrinol. Metab. 2010 298 1 E49 E58 19887598 PMC2806111
  27. [33]Mihalik S.J. Goodpaster B.H. Kelley D.E. Chace D.H. Vockley J. Toledo F.G.S. DeLany J.P. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 2010 18 9 1695 1700 20111019 PMC3984458
  28. [34]Newgard C.B. An J. Bain J.R. Muehlbauer M.J. Stevens R.D. Lien L.F. Haqq A.M. Shah S.H. Arlotto M. Slentz C.A. Rochon J. Gallup D. Ilkayeva O. Wenner B.R. Yancy W.S. Eisenson H. Musante G. Surwit R.S. Millington D.S. Butler M.D. Svetkey L.P. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009 9 4 311 326 19356713 PMC3640280
  29. [35]Adams S.H. Hoppel C.L. Lok K.H. Zhao L. Wong S.W. Minkler P.E. Hwang D.H. Newman J.W. Garvey W.T. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J. Nutr. 2009 139 6 1073 1081 19369366 PMC2714383
  30. [37]Brown D.A. Perry J.B. Allen M.E. Sabbah H.N. Stauffer B.L. Shaikh S.R. Cleland J.G.F. Colucci W.S. Butler J. Voors A.A. Anker S.D. Pitt B. Pieske B. Filippatos G. Greene S.J. Gheorghiade M. Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. Nat. Rev. Cardiol. 2017 14 4 238 250 28004807 PMC5350035
  31. [38]Halestrap A.P. Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim. Biophys. Acta 2009 1787 11 1402 1415 19168026
  32. [40]Rontoyanni V.G. Nunez Lopez O. Fankhauser G.T. Cheema Z.F. Rasmussen B.B. Porter C. Mitochondrial Bioenergetics in the Metabolic Myopathy Accompanying Peripheral Artery Disease. Front. Physiol. 2017 8 141 28348531 PMC5346567
  33. [42]Onyango I.G. Dennis J. Khan S.M. Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies. Aging Dis. 2016 7 2 201 214 27114851 PMC4809610
  34. [44]Manczak M. Anekonda T.S. Henson E. Park B.S. Quinn J. Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006 15 9 1437 1449 16551656
  35. [45]Moreira P.I. Zhu X. Wang X. Lee H-G. Nunomura A. Petersen R.B. Perry G. Smith M.A. Mitochondria: A therapeutic target in neurodegeneration. Biochim. Biophys. Acta 2010 1802 1 212 220 19853657 PMC2790540
  36. [46]Beal M.F. Mitochondria and neurodegeneration. Novartis Found. Symp. 2007 287 183 192 18074639
  37. [48]Galter D. Pernold K. Yoshitake T. Lindqvist E. Hoffer B. Kehr J. Larsson N-G. Olson L. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson’s disease. Genes Brain Behav. 2010 9 2 173 181 20002202 PMC4154513
  38. [49]Carmo C. Naia L. Lopes C. Rego A.C. Mitochondrial Dysfunction in Huntington’s Disease. Adv. Exp. Med. Biol. 2018 1049 59 83 29427098
  39. [50]Beal M.F. Brouillet E. Jenkins B.G. Ferrante R.J. Kowall N.W. Miller J.M. Storey E. Srivastava R. Rosen B.R. Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993 13 10 4181 4192 7692009 PMC6576392
  40. [51]Shi P. Gal J. Kwinter D.M. Liu X. Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2010 1802 1 45 51 19715760 PMC2790551
  41. [52]Igoudjil A. Magrané J. Fischer L.R. Kim H.J. Hervias I. Dumont M. Cortez C. Glass J.D. Starkov A.A. Manfredi G. In vivo pathogenic role of mutant SOD1 localized in the mitochondrial intermembrane space. J. Neurosci. 2011 31 44 15826 15837 22049426 PMC3249412
  42. [54]Sperl W. Skladal D. Gnaiger E. Wyss M. Mayr U. Hager J. Gellerich F.N. High resolution respirometry of permeabilized skeletal muscle fibers in the diagnosis of neuromuscular disorders. Mol. Cell. Biochem. 1997 174 1-2 71 78 9309668
  43. [55]Vila M.C. Rayavarapu S. Hogarth M.W. Van der Meulen J.H. Horn A. Defour A. Takeda S. Brown K.J. Hathout Y. Nagaraju K. Jaiswal J.K. Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy. Cell Death Differ. 2017 24 2 330 342 27834955 PMC5299714
  44. [57]Rygiel K.A. Miller J. Grady J.P. Rocha M.C. Taylor R.W. Turnbull D.M. Mitochondrial and inflammatory changes in sporadic inclusion body myositis. Neuropathol. Appl. Neurobiol. 2015 41 3 288 303 24750247 PMC4833191
  45. [58]Balk R.A. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? Virulence 2014 5 1 20 26 24280933 PMC3916374
  46. [59]Rangel-Frausto M.S. Pittet D. Costigan M. Hwang T. Davis C.S. Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study. JAMA 1995 273 2 117 123 7799491
  47. [60]Zakharova V.V. Pletjushkina O.Y. Zinovkin R.A. Popova E.N. Chernyak B. V Mitochondria-Targeted Antioxidants and Uncouplers of Oxidative Phosphorylation in Treatment of the Systemic Inflammatory Response Syndrome (SIRS). J. Cell. Physiol. 2017 232 5 904 912 27684052
  48. [62]Zhong Z. Liang S. Sanchez-Lopez E. He F. Shalapour S. Lin X. Wong J. Ding S. Seki E. Schnabl B. Hevener A.L. Greenberg H.B. Kisseleva T. Karin M. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 2018 560 7717 198 203 30046112 PMC6329306
  49. [64]Prikhodko A.S. Vitushkina M.V. Zinovkina L.A. Popova E.N. Zinovkin R.A. Priming of human neutrophils is necessary for their activation by extracellular DNA. Biochem. 2016 81 6 609 614 27301289
  50. [65]Chakraborty K. Raundhal M. Chen B.B. Morse C. Tyurina Y.Y. Khare A. Oriss T.B. Huff R. Lee J.S. St Croix C.M. Watkins S. Mallampalli R.K. Kagan V.E. Ray A. Ray P. The mito-DAMP cardiolipin blocks IL-10 production causing persistent inflammation during bacterial pneumonia. Nat. Commun. 2017 8 13944 28074841 PMC5241690
  51. [66]Raoof M. Zhang Q. Itagaki K. Hauser C.J. Mitochondrial Peptides Are Potent Immune Activators That Activate Human Neutrophils Via FPR-1. J. Trauma Inj. Infect. Crit. Care 2010 68 6 1328 1334 20539176
  52. [67]Oliveira P.J. Mitochondrial Biology and Experimental Therapeutics. Cham Springer 2018
  53. [69]Harman D. The biologic clock: the mitochondria? J. Am. Geriatr. Soc. 1972 20 4 145 147 5016631
  54. [71]Schriner S.E. Linford N.J. Martin G.M. Treuting P. Ogburn C.E. Emond M. Coskun P.E. Ladiges W. Wolf N. Van Remmen H. Wallace D.C. Rabinovitch P.S. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 2005 308 5730 1909 1911 15879174
  55. [72]Kennedy S.R. Salk J.J. Schmitt M.W. Loeb L.A. Ultra-sensitive sequencing reveals an age-related increase in somatic mitochondrial mutations that are inconsistent with oxidative damage. PLoS Genet. 2013 9 9 e1003794 24086148 PMC3784509
  56. [73]Chung H.Y. Cesari M. Anton S. Marzetti E. Giovannini S. Seo A.Y. Carter C. Yu B.P. Leeuwenburgh C. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res. Rev. 2009 8 1 18 30 18692159 PMC3782993
  57. [74]Judge S. Jang Y.M. Smith A. Hagen T. Leeuwenburgh C. Age-associated increases in oxidative stress and antioxidant enzyme activities in cardiac interfibrillar mitochondria: implications for the mitochondrial theory of aging. FASEB J. 2005 19 3 419 421 15642720
  58. [75]Ungvari Z. Orosz Z. Labinskyy N. Rivera A. Xiangmin Z. Smith K. Csiszar A. Increased mitochondrial H2O2 production promotes endothelial NF-kappaB activation in aged rat arteries. Am. J. Physiol. Heart Circ. Physiol. 2007 293 1 H37 H47 17416599
  59. [76]Dai D-F. Rabinovitch P.S. Ungvari Z. Mitochondria and cardiovascular aging. Circ. Res. 2012 110 8 1109 1124 22499901 PMC3867977
  60. [80]Gray M.W. Burger G. Lang B.F. Mitochondrial evolution. Science 1999 283 5407 1476 1481 10066161
  61. [81]Adam-Vizi V. Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol. Sci. 2006 27 12 639 645 17056127
  62. [82]Kagan V.E. Borisenko G.G. Tyurina Y.Y. Tyurin V.A. Jiang J. Potapovich A.I. Kini V. Amoscato A.A. Fujii Y. Oxidative lipidomics of apoptosis: redox catalytic interactions of cytochrome c with cardiolipin and phosphatidylserine. Free Radic. Biol. Med. 2004 37 12 1963 1985 15544916
  63. [83]Pfanner N. Geissler A. Versatility of the mitochondrial protein import machinery. Nat. Rev. Mol. Cell Biol. 2001 2 5 339 349 11331908
  64. [84]Liberman E.A. Topaly V.P. Tsofina L.M. Jasaitis A.A. Skulachev V.P. Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature 1969 222 5198 1076 1078 5787094
  65. [85]Smith R.A. Porteous C.M. Coulter C.V. Murphy M.P. Selective targeting of an antioxidant to mitochondria. Eur. J. Biochem. 1999 263 3 709 716 10469134
  66. [86]Amorim R. Benfeito S. Teixeira J. Cagide F. Oliveira P.J. Borges F. Mitochondrial Biology and Experimental Therapeutics. Oliveira P.J. Cham Springer 2018 333 358
  67. [87]Weissig V. Mitochondrial Medicine. Weissig V. Edeas M. Humana Press 2015 Vol. II 1 11
  68. [88]D’Souza G.G.M. Boddapati S.V. Weissig V. Mitochondrial leader sequence-plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondria. Mitochondrion 2005 5 5 352 358 16154389
  69. [89]Zhao K. Zhao G-M. Wu D. Soong Y. Birk A.V. Schiller P.W. Szeto H.H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem. 2004 279 33 34682 34990 15178689
  70. [90]Birk A.V. Liu S. Soong Y. Mills W. Singh P. Warren J.D. Seshan S.V. Pardee J.D. Szeto H.H. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J. Am. Soc. Nephrol. 2013 24 8 1250 1261 23813215 PMC3736700
  71. [92]Cerrato C.P. Langel Ü. Cell-Penetrating Peptides Targeting Mitochondria. Mitochondrial Biology and Experimental Therapeutics. Cham Springer International Publishing 2018 593 611
  72. [93]Szeto H.H. Birk A.V. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin. Pharmacol. Ther. 2014 96 6 672 683 25188726 PMC4267688
  73. [94]Heijne G. von Mitochondrial targeting sequences may form amphiphilic helices. EMBO J. 1986 5 6 1335 1342 3015599 PMC1166945
  74. [95]Neupert W. Herrmann J.M. Translocation of proteins into mitochondria. Annu. Rev. Biochem. 2007 76 723 749 17263664
  75. [96]Flierl A. Jackson C. Cottrell B. Murdock D. Seibel P. Wallace D.C. Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. Mol. Ther. 2003 7 4 550 557 12727119
  76. [97]Yu H. Koilkonda R.D. Chou T-H. Porciatti V. Ozdemir S.S. Chiodo V. Boye S.L. Boye S.E. Hauswirth W.W. Lewin A.S. Guy J. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber’s hereditary optic neuropathy in a mouse model. Proc. Natl. Acad. Sci. USA 2012 109 20 E1238 E1247 22523243 PMC3356643
  77. [98]Cha M-Y. Han S-H. Son S.M. Hong H-S. Choi Y-J. Byun J. Mook-Jung I. Mitochondria-specific accumulation of amyloid β induces mitochondrial dysfunction leading to apoptotic cell death. PLoS One 2012 7 4 e34929 22514691 PMC3325919
  78. [99]Korshunov S.S. Skulachev V.P. Starkov A.A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett. 1997 416 1 15 18 9369223
  79. [100]Antonenko Y.N. Avetisyan A.V. Bakeeva L.E. Chernyak B.V. Chertkov V.A. Domnina L.V. Ivanova O.Y. Izyumov D.S. Khailova L.S. Klishin S.S. Korshunova G.A. Lyamzaev K.G. Muntyan M.S. Nepryakhina O.K. Pashkovskaya A.A. Pletjushkina O.Y. Pustovidko A.V. Roginsky V.A. Rokitskaya T.I. Ruuge E.K. Saprunova V.B. Severina I.I. Simonyan R.A. Skulachev I.V. Skulachev M.V. Sumbatyan N.V. Sviryaeva I.V. Tashlitsky V.N. Vassiliev J.M. Vyssokikh M.Y. Yaguzhinsky L.S. Zamyatnin A.A. Skulachev V.P. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: synthesis and in vitro studies. Biochemistry (Mosc.) 2008 73 12 1273 1287 19120014
  80. [101]Fink B.D. Herlein J.A. Yorek M.A. Fenner A.M. Kerns R.J. Sivitz W.I. Bioenergetic effects of mitochondrial-targeted coenzyme Q analogs in endothelial cells. J. Pharmacol. Exp. Ther. 2012 342 3 709 719 22661629 PMC3422527
  81. [103]Snow B.J. Rolfe F.L. Lockhart M.M. Frampton C.M. O’Sullivan J.D. Fung V. Smith R.A.J. Murphy M.P. Taylor K.M. Protect Study Group A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov. Disord. 2010 25 11 1670 1674 20568096
  82. [105]Petrov A. Perekhvatova N. Skulachev M. Stein L. Ousler G. SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model. Adv. Ther. 2016 33 1 96 115 26733410 PMC4735228
  83. [106]Sies H. Total antioxidant capacity: Appraisal of a concept. J. Nutr. 2007 137 6 1493 1495 17513413
  84. [107]Gasparovic A.C. Jaganjac M. Mihaljevic B. Sunjic S.B. Zarkovic N. Assays for the measurement of lipid peroxidation. Methods Mol. Biol. 2013 965 283 296 23296666
  85. [109]Skulachev V.P. Antonenko Y.N. Cherepanov D.A. Chernyak B.V. Izyumov D.S. Khailova L.S. Klishin S.S. Korshunova G.A. Lyamzaev K.G. Pletjushkina O.Y. Roginsky V.A. Rokitskaya T.I. Severin F.F. Severina I.I. Simonyan R.A. Skulachev M.V. Sumbatyan N.V. Sukhanova E.I. Tashlitsky V.N. Trendeleva T.A. Vyssokikh M.Y. Zvyagilskaya R.A. Prevention of cardiolipin oxidation and fatty acid cycling as two antioxidant mechanisms of cationic derivatives of plastoquinone (SkQs). Biochim. Biophys. Acta Bioenerg. 2010 1797 6-7 878 889 20307489
  86. [110]Severin F.F. Severina I.I. Antonenko Y.N. Rokitskaya T.I. Cherepanov D.A. Mokhova E.N. Vyssokikh M.Y. Pustovidko A.V. Markova O.V. Yaguzhinsky L.S. Korshunova G.A. Sumbatyan N.V. Skulachev M.V. Skulachev V.P. Penetrating cation/fatty acid anion pair as a mitochondria-targeted protonophore. Proc. Natl. Acad. Sci. USA 2010 107 2 663 668 20080732 PMC2818959
  87. [111]Feniouk B.A. Skulachev V.P. Cellular and Molecular Mechanisms of Action of Mitochondria-Targeted Antioxidants. Curr. Aging Sci. 2017 10 1 41 48 27659264
  88. [112]Asin-Cayuela J. Manas A-R.B. James A.M. Smith R.A.J. Murphy M.P. Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett. 2004 571 1-3 9 16 15280009
  89. [113]Pond S.M. Tozer T.N. First-pass elimination. Basic concepts and clinical consequences. Clin. Pharmacokinet. ••• 9 1 1 25 6362950
  90. [115]Smith R.A.J. Porteous C.M. Gane A.M. Murphy M.P. Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. USA 2003 100 9 5407 5412 12697897 PMC154358
  91. [116]Kezic A. Spasojevic I. Lezaic V. Bajcetic M. Mitochondria-Targeted Antioxidants: Future Perspectives in Kidney Ischemia Reperfusion Injury. Oxid. Med. Cell. Longev. 2016 2016 1 12 PMC4894993 27313826
  92. [118]Braakhuis A.J. Nagulan R. Somerville V. The Effect of MitoQ on Aging-Related Biomarkers: A Systematic Review and Meta-Analysis. Oxid. Med. Cell. Longev. 2018 2018 8575263 30116495 PMC6079400
  93. [119]Shabalina I.G. Vyssokikh M.Y. Gibanova N. Csikasz R.I. Edgar D. Hallden-Waldemarson A. Rozhdestvenskaya Z. Bakeeva L.E. Vays V.B. Pustovidko A.V. Skulachev M.V. Cannon B. Skulachev V.P. Nedergaard J. Improved health-span and lifespan in mtDNA mutator mice treated with the mitochondrially targeted antioxidant SkQ1. Aging (Albany NY) 2017 9 2 315 339 28209927 PMC5361666
  94. [120]Ng L.F. Gruber J. Cheah I.K. Goo C.K. Cheong W.F. Shui G. Sit K.P. Wenk M.R. Halliwell B. The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease. Free Radic. Biol. Med. 2014 71 390 401 24637264
  95. [121]Shill D.D. Southern W.M. Willingham T.B. Lansford K.A. McCully K.K. Jenkins N.T. Mitochondria-specific antioxidant supplementation does not influence endurance exercise training-induced adaptations in circulating angiogenic cells, skeletal muscle oxidative capacity or maximal oxygen uptake. J. Physiol. 2016 594 23 7005 7014 27501153 PMC5134375
  96. [123]van der Loo B. Labugger R. Skepper J.N. Bachschmid M. Kilo J. Powell J.M. Palacios-Callender M. Erusalimsky J.D. Quaschning T. Malinski T. Gygi D. Ullrich V. Lüscher T.F. Enhanced peroxynitrite formation is associated with vascular aging. J. Exp. Med. 2000 192 12 1731 1744 11120770 PMC2213492
  97. [124]Bachschmid M.M. Schildknecht S. Matsui R. Zee R. Haeussler D. Cohen R.A. Pimental D. Loo B. van der Vascular aging: chronic oxidative stress and impairment of redox signaling-consequences for vascular homeostasis and disease. Ann. Med. 2013 45 1 17 36 22380696 PMC3717565
  98. [125]Weidinger A. Müllebner A. Paier-Pourani J. Banerjee A. Miller I. Lauterböck L. Duvigneau J.C. Skulachev V.P. Redl H. Kozlov A.V. Vicious inducible nitric oxide synthase-mitochondrial reactive oxygen species cycle accelerates inflammatory response and causes liver injury in rats. Antioxid. Redox Signal. 2015 22 7 572 586 25365698
  99. [126]Manskikh V.N. Gancharova O.S. Nikiforova A.I. Krasilshchikova M.S. Shabalina I.G. Egorov M.V. Karger E.M. Milanovsky G.E. Galkin I.I. Skulachev V.P. Zinovkin R.A. Age-associated murine cardiac lesions are attenuated by the mitochondria-targeted antioxidant SkQ1. Histol. Histopathol. 2015 30 3 353 360 25323729
  100. [127]Galkin I.I. Pletjushkina O.Y. Zinovkin R.A. Zakharova V.V. Birjukov I.S. Chernyak B.V. Popova E.N. Mitochondria-targeted antioxidants prevent TNFα-induced endothelial cell damage. Biochemistry (Mosc.) 2014 79 2 124 130 24794727
  101. [128]Mao P. Manczak M. Shirendeb U.P. Reddy P.H. MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochim. Biophys. Acta 2013 1832 12 2322 2331 24055980 PMC3830526
  102. [129]Korenaga M. Wang T. Li Y. Showalter L.A. Chan T. Sun J. Weinman S.A. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J. Biol. Chem. 2005 280 45 37481 37488 16150732
  103. [130]Chacko B.K. Srivastava A. Johnson M.S. Benavides G.A. Chang M.J. Ye Y. Jhala N. Murphy M.P. Kalyanaraman B. Darley-Usmar V.M. Mitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis. Hepatology 2011 54 1 153 163 21520201 PMC3125473
  104. [131]Lukashev A.N. Skulachev M.V. Ostapenko V. Savchenko A.Y. Pavshintsev V.V. Skulachev V.P. Advances in development of rechargeable mitochondrial antioxidants. Prog. Mol. Biol. Transl. Sci. 2014 127 251 265 25149221
  105. [132]Skulachev V.P. Anisimov V.N. Antonenko Y.N. Bakeeva L.E. Chernyak B.V. Erichev V.P. Filenko O.F. Kalinina N.I. Kapelko V.I. Kolosova N.G. Kopnin B.P. Korshunova G.A. Lichinitser M.R. Obukhova L.A. Pasyukova E.G. Pisarenko O.I. Roginsky V.A. Ruuge E.K. Senin I.I. Severina I.I. Skulachev M.V. Spivak I.M. Tashlitsky V.N. Tkachuk V.A. Vyssokikh M.Y. Yaguzhinsky L.S. Zorov D.B. An attempt to prevent senescence: a mitochondrial approach. Biochim. Biophys. Acta 2009 1787 5 437 461 19159610
  106. [133]Markovets A.M. Fursova A.Z. Kolosova N.G. Therapeutic action of the mitochondria-targeted antioxidant SkQ1 on retinopathy in OXYS rats linked with improvement of VEGF and PEDF gene expression. PLoS One 2011 6 7 e21682 21750722 PMC3130050
  107. [134]Iomdina E.N. Khoroshilova-Maslova I.P. Robustova O.V. Averina O.A. Kovaleva N.A. Aliev G. Reddy V.P. Zamyatnin A.A. Skulachev M.V. Senin I.I. Skulachev V.P. Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits. Front. Biosci. Landmark Ed. 2015 20 1 892 901 25553485
  108. [136]Brzheskiy V.V. Efimova E.L. Vorontsova T.N. Alekseev V.N. Gusarevich O.G. Shaidurova K.N. Ryabtseva A.A. Andryukhina O.M. Kamenskikh T.G. Sumarokova E.S. Miljudin E.S. Egorov E.A. Lebedev O.I. Surov A.V. Korol A.R. Nasinnyk I.O. Bezditko P.A. Muzhychuk O.P. Vygodin V.A. Yani E.V. Savchenko A.Y. Karger E.M. Fedorkin O.N. Mironov A.N. Ostapenko V. Popeko N.A. Skulachev V.P. Skulachev M.V. Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome. Adv. Ther. 2015 32 12 1263 1279 26660938 PMC4679790
  109. [137]Zernii E.Y. Gancharova O.S. Baksheeva V.E. Golovastova M.O. Kabanova E.I. Savchenko M.S. Tiulina V.V. Sotnikova L.F. Zamyatnin A.A. Philippov P.P. Senin I.I. Mitochondria-Targeted Antioxidant SkQ1 Prevents Anesthesia-Induced Dry Eye Syndrome. Oxid. Med. Cell. Longev. 2017 2017 1 17 PMC5660788 29158874
  110. [138]Callender S.P. Mathews J.A. Kobernyk K. Wettig S.D. Microemulsion utility in pharmaceuticals: Implications for multi-drug delivery. Int. J. Pharm. 2017 526 1-2 425 442 28495500

Cited by

Sorted by citations

Authors
Zinovkin, R. A., & Zamyatnin, A. A.
Affiliations
Lomonosov Moscow State University (RU)
Corresponding author
  • Zinovkin, Roman A.
  • Zamyatnin, Andrey A.
ORCID
Venue
Current Molecular Pharmacology
Publisher
Elsevier BV
Published
2019-07-29
Volume
12
Issue
3
Pages
202-214
ISSN
1874-4672 (ISSN-L)
DOI
10.2174/1874467212666181127151059
PMC
PMC6875871
OpenAlex
W2902944709
Cited by
209
References
26
Citations by year
2026: 25 · 2025: 31 · 2024: 37 · 2023: 34 · 2022: 40 · 2021: 21 · 2020: 16 · 2019: 5
FWCI
1.03
Type
journal article
Language
en
Open access
Locations
  • Current Molecular Pharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Russian Foundation for Basic Research (18-04-01110)
  • Russian Science Foundation (14-24-00107)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
Keywords
mitochondria-targeted drugs, mitochondrial dysfunction, MitoQ, SkQ1, lipophilic cations, antioxidants, mitochondrial disease, aging, cardiovascular disease, neurological disorders, metabolic disorders, clinical trials
MeSH terms
Animals, Antioxidants, Humans, Mitochondria, Organophosphorus Compounds, Plastoquinone, Ubiquinone, Drug Delivery Systems, Reactive Oxygen Species, Oxidative Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review